Sensicutan^® Cream

For Neurodermatitis

• steroid-free, long-term and low risk therapeutic agent
• potent anti-inflammatory agent
• fast relief of itching (for acute and chronic eczema)
• excellent skin tolerance
• pleasant cosmetic tolerance

Brief Information

Composition:

levomenol (alpha-bisabolol)	0.30 g
sodium heparin	20 000 IU
emulsion cream base	ad 100.00 g

Drug Presentation and Package Sizes:

30 g Sensicutan® Cream

80 g Sensicutan® Cream

Indications:

Acute and chronic eczema, dermatitis (e.g. atopic dermatitis / neurodermatitis), inflammatory
allergic skin diseases, prurigo (itching).

Mode of Administration and Dosage Directions:

For external use: If not otherwise directed, apply to the affected skin areas 2-3 times daily; also
suited for cream / occlusive dressings.

Contraindications:

Hypersensitivity to heparin or any other ingredient contained in Sensicutan^® Cream.

Side Effects:

Allergic skin reactions may occur in very rare cases of patients with extremely sensitive skin. In general, these skin symptoms disappear quickly. A physician should be consulted if a specific allergic reaction occurs.

Drug Interaction:

No drug interactions are known.

Sensicutan® Cream
Stops itching, heals eczematous skin

Pharmacological Profile

The process involved in the development
and spread of eczema is complex and multifaceted and is frequently of diverse pathogenesis. Therefore, in order to treat eczematous skin symptoms with a specific and promising therapy, it is important that the treatment contain various dermatologically effective substances.

Stereoid-free local therapy

Indications: Eczema, neurodermatitis, prurigo

Sensicutan^® Cream is a steroid-free local therapeutic agent for the treatment of skin disorders which fall under the general disease form eczema and which are frequently accompanied by itching, such as

• acute and chronic eczema
• dermatitis (e.g. atopic dermatitis / neurodermatitis)
• allergic skin symptoms

Highly-developed emulsion system

The emulsion system of Sensicutan^® Cream is highly-developed in terms of its galenic and cosmetic properties and, in its moisturizing cream base, contains the two active substances

• levomenol (alpha-bisabolol) and
• sodium heparin.

Balanced combination

The well-matched and balanced combination provides for a rapid onset of action characterized by

• potent anti-inflammatory action and
•  fast relief of itching.

Typical eczema symptoms

Typical eczematous skin symptoms such as

• burning
• redness
• swelling
• peeling / scaling

recede quickly with Sensicutan^® therapy which is generally well tolerated by the skin.

Good skin tolercance / Non-irritating to skin

Especially suited for sensitive skin

Sensicutan^® Cream is also suited for sensitive skin areas as well as being particularly suited for the treatment of neurodermatitis which is seen more and more frequently in children and infants.

Long-term therapeutic agent

Sensicutan^® Cream can be employed for long-term therapy of very persistent allergic skin diseases and eczema equally well in patients with dry, normal and greasy / oily skin.

Sensicutan^® Cream soothes and heals skin irritated and damaged by scratching.

Mechanism of action

The cutaneous anti-inflammatory agent
The mode of action involving the specific anti-inflammatory effect is of primary importance for the treatment of eczema and allergic skin diseases.

Good skin penetration

Specific antiphlogistic efficacy
Both active substances contained in SENSICUTAN^® Cream - namely levomenol (alpha-bisabolol) and sodium heparin - penetrate the skin well. It is here that they exert their specific antiphlogistic action and inhibit inflammation mediators. As a result, reddening of the skin (erythema) and burning - two typical symptoms of eczema - subside.

Literature:

P. ARENBERGER et al.:
Clinicial Double-blind study: Evaluation of the efficacy and safety of Sensicutan® with Dermatitis atopica and eczema caused by allergy in comparison with placebo (in publication 2000)

SELZLE, D.:
Expert report on the application of Sensicutan® with Dermatitis atopica and chronic eczemas (1993)

B. HAHN, J. HÖLZL:
Arzneim.-Forsch. 37, (1), Nr. 6, (1987), 716-720

J.RING, H. FRÖHLICH:
"Wirkstoffe in der dermatologischen Therapie", Springer-Verlag, Berlin - Heidelberg - New York - Tokyo (1985), 190-191

H. WAGNER:
"Pharmazeutische Biologie" 3. Aufl., Gustav-Fischer-Verlag, Stuttgart - New York, (1985), 75